文章摘要
唐小铁,徐 洁,王丽媛,于 洋,崔学彬,孙维言.阿托伐他汀联合厄贝沙坦对老年腹膜透析患者的氧化应激及微炎症状态的影响[J].,2019,19(20):3908-3911
阿托伐他汀联合厄贝沙坦对老年腹膜透析患者的氧化应激及微炎症状态的影响
Effects of Atorvastatin Combined with Irbesartan on Oxidative Stress and Microinflammation in Elderly Patients Undergoing Peritoneal Dialysis
投稿时间:2019-04-05  修订日期:2019-04-28
DOI:10.13241/j.cnki.pmb.2019.20.024
中文关键词: 阿托伐他汀  厄贝沙坦  老年  腹膜透析  氧化应激  微炎症
英文关键词: Atorvastatin  Irbesartan  Elderly  Peritoneal dialysis  Oxidative stress  Microinflammation
基金项目:湖北省卫计委联合基金面上项目(WJ2018H0107);武汉市卫计委一般项目(WX17D27)
作者单位E-mail
唐小铁 武汉科技大学附属普仁医院肾内科 湖北 武汉 430081 15717107215@139.com 
徐 洁 武汉科技大学附属普仁医院肾内科 湖北 武汉 430081  
王丽媛 武汉科技大学附属普仁医院肾内科 湖北 武汉 430081  
于 洋 武汉科技大学附属普仁医院肾内科 湖北 武汉 430081  
崔学彬 武汉科技大学附属普仁医院肾内科 湖北 武汉 430081  
孙维言 武汉科技大学附属普仁医院肾内科 湖北 武汉 430081  
摘要点击次数: 854
全文下载次数: 609
中文摘要:
      摘要 目的:研究阿托伐他汀联合厄贝沙坦对老年腹膜透析(PD)患者的氧化应激(OS)及微炎症(MI)状态的影响。方法:选择2017年1月到2018年12月在我院收治的老年尿毒症患者96例纳入本次研究。按照随机数字表法将患者分成观察组及对照组各48例,两组均给予常规PD治疗,对照组另给予阿托伐他汀,观察组在对照组的用药基础上另增用厄贝沙坦,两组均治疗3个月后对比两组治疗前及治疗3个月后的OS指标,包括丙二醛(MDA)、超氧化物歧化酶(SOD)及晚期蛋白质氧化产物(AOPP),MI指标,包括C反应蛋白(CRP)、β2-微球蛋白(β2-Mg)及降钙素原(PCT)。结果:治疗后观察组的AOPP和MDA水平均分别低于对照组,SOD水平明显高于对照组,差异均有统计学意义(均P<0.05)。治疗后观察组的CRP、β2-MG及PCT水平均分别低于对照组,差异均有统计学意义(均P<0.05)。按照Spearman法对患者治疗后的OS指标与MI指标的相关性分析后可知,AOPP和MDA均分别与CRP、β2-MG及PCT呈正相关(均P<0.05),而SOD则分别与CRP、β2-MG及PCT呈负相关(均P<0.05)。结论:阿托伐他汀联合厄贝沙坦可有效改善老年PD患者机体的OS及MI状态。临床可通过监测MDA、SOD、AOPP、CRP、β2-MG及PCT等指标水平,全面地掌握患者的病情,从而更好地服务后续治疗。
英文摘要:
      ABSTRACT Objective: To study the effects of atorvastatin combined with irbesartan on oxidative stress (OS) and microinflammation (MI) in elderly patients undergoing peritoneal dialysis (PD). Methods: 96 elderly uremic patients who were followed up in our hospital from January 2017 to December 2018 were enrolled in this study. According to the random number table method, the patients were divided into observation group and control group, 48 cases in each group. The two groups were given routine PD treatment, the control group was given atorvastatin, and the observation group was given irbesartan on the basis of the control group. The were OS indices and MI indices compared before and after 3 months of treatment in both groups, which OS indices including malondialdehyde (MDA), superoxide dismutase (SOD), advanced protein oxidation products (AOPP), MI indices including C-reactive protein (CRP), β2-microglobulin (β2-Mg) and procalcitonin (PCT). Results: After treatment, the levels of AOP and MDA in the observation group were lower than those in the control group, and the levels of SOD in the observation group were significantly higher than those in the control group (all P<0.05). After treatment, the CRP, β2-Mg and PCT levels in the observation group were lower than those in the control group, with statistical significance (all P<0.05). According to Spearman's analysis of the correlation between OS indices and MI indices after treatment, AOPP and MDA were positively correlated with CRP, β2-Mg and PCT (all P<0.05), while SOD was negatively correlated with CRP, β2-Mg and PCT (all P<0.05). Conclusion: Atorvastatin combined with irbesartan can effectively improve the OS and MI status of elderly patients undergoing PD. Clinical monitoring of MDA, SOD, AOPP, CRP, β2-Mg, PCT and other indicators can comprehensively grasp the patient's condition, so as to better serve the follow-up treatment.
查看全文   查看/发表评论  下载PDF阅读器
关闭